Baidu
map

Diabetes Res Clin Pr:米格列醇/米格列奈联合比单药治疗更有效

2013-06-06 Diabetes Res Clin Pract 丁香园

在日本2型糖尿病患者,为了评估米格列醇与米格列奈单独或联合使用对代谢谱和肠促胰岛素分泌的功效。来自日本川崎医科大学的Mitsuru Hashiramoto教授及其团队进行了一项研究,该研究发现米格列醇/米格列奈联合使用比单药治疗在减少餐后血糖波动和同时减少额外胰岛素分泌,改善血糖控制方面更有效。该研究同时证明米格列醇和米格列奈对肠促胰岛素分泌的影响有显著差异。该研究结果在线发表在5月24日的《糖尿

在日本2型糖尿病患者,为了评估米格列醇与米格列奈单独或联合使用对代谢谱和肠促胰岛素分泌的功效。来自日本川崎医科大学的Mitsuru Hashiramoto教授及其团队进行了一项研究,该研究发现米格列醇/米格列奈联合使用比单药治疗在减少餐后血糖波动和同时减少额外胰岛素分泌,改善血糖控制方面更有效。该研究同时证明米格列醇和米格列奈对肠促胰岛素分泌的影响有显著差异。该研究结果在线发表在5月24日的《糖尿病研究与临床实践》(Diabetes research and clinical practice)杂志上。

该研究中,饮食和运动基础上加用或不加用二甲双胍的患者被随机分配接受米格列醇、米格列奈、或联用米格列醇与米格列奈,每日三次,治疗12周。

该研究结果表明,第12周,所有三组HbA1c显著下降(p<0.001),1、5–AG显著增加(p<0.001),在联合治疗组观察到最显著地变化。通过进餐负荷试验证明所有三种干预有效改善餐后高血糖,但米格列醇组血清胰岛素浓度没有增加。在之前没有使用二甲双胍治疗的患者亚组中,在最初联合治疗的患者达到更快和更好的血糖控制。在进餐负荷后,仅在米格列醇单药治疗的患者血清总GLP–1显著增加(p<0.05),并且12周后,使用米格列醇的患者血清总GIP显著下降(p<0.01)。

该研究发现,米格列醇/米格列奈联合使用比单药治疗在减少餐后血糖波动和同时减少额外胰岛素分泌,改善血糖控制方面更有效。该研究同时证明米格列醇和米格列奈对肠促胰岛素分泌的影响有显著差异。

Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus.
AIM
To evaluate the efficacy of miglitol and mitiglinide alone or in combination on the metabolic profile and incretin secretion in Japanese type 2 diabetes patients.
METHODS
Patients on diet and exercise with or without metformin, were randomized to receive either miglitol, mitiglinide, or a combination, three times daily for 12 weeks.
RESULTS
At 12 weeks, HbA1c decreased significantly (p<0.001) and 1,5-AG increased significantly (p<0.001) in all three groups, with the greatest change seen with combination therapy. Effective improvement of postprandial hyperglycemia was demonstrated by a meal-loading test in all three interventions but serum insulin concentration was not increased by miglitol. In a subset of patients without prior metformin administration, faster and better glycemic control was achieved with the initial combination. After meal loading, serum total GLP-1 significantly increased only with miglitol monotherapy (p<0.05) and serum total GIP significantly decreased (p<0.01) in the arms employing miglitol after 12 weeks.
CONCLUSION
Miglitol/mitiglinide combination is more potent than monotherapy in improving glycemic control through the reduction of postprandial glucose excursion and the simultaneous sparing of additional insulin secretion. A marked difference in the effects of miglitol and mitiglinide on incretin secretion was also demonstrated.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636687, encodeId=0820163668ede, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Apr 02 22:26:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759299, encodeId=d66e1e592994f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Sep 09 06:26:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901104, encodeId=965e190110417, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Oct 26 01:26:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687670, encodeId=b581168e67091, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Fri Dec 06 14:26:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803921, encodeId=9f251803921b7, content=<a href='/topic/show?id=41bde6100af' target=_blank style='color:#2F92EE;'>#米格列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76100, encryptionId=41bde6100af, topicName=米格列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Oct 24 02:26:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803920, encodeId=424718039200e, content=<a href='/topic/show?id=b578e6099e8' target=_blank style='color:#2F92EE;'>#米格列奈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76099, encryptionId=b578e6099e8, topicName=米格列奈)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 24 05:26:00 CST 2013, time=2013-08-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636687, encodeId=0820163668ede, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Apr 02 22:26:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759299, encodeId=d66e1e592994f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Sep 09 06:26:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901104, encodeId=965e190110417, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Oct 26 01:26:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687670, encodeId=b581168e67091, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Fri Dec 06 14:26:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803921, encodeId=9f251803921b7, content=<a href='/topic/show?id=41bde6100af' target=_blank style='color:#2F92EE;'>#米格列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76100, encryptionId=41bde6100af, topicName=米格列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Oct 24 02:26:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803920, encodeId=424718039200e, content=<a href='/topic/show?id=b578e6099e8' target=_blank style='color:#2F92EE;'>#米格列奈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76099, encryptionId=b578e6099e8, topicName=米格列奈)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 24 05:26:00 CST 2013, time=2013-08-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636687, encodeId=0820163668ede, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Apr 02 22:26:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759299, encodeId=d66e1e592994f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Sep 09 06:26:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901104, encodeId=965e190110417, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Oct 26 01:26:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687670, encodeId=b581168e67091, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Fri Dec 06 14:26:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803921, encodeId=9f251803921b7, content=<a href='/topic/show?id=41bde6100af' target=_blank style='color:#2F92EE;'>#米格列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76100, encryptionId=41bde6100af, topicName=米格列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Oct 24 02:26:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803920, encodeId=424718039200e, content=<a href='/topic/show?id=b578e6099e8' target=_blank style='color:#2F92EE;'>#米格列奈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76099, encryptionId=b578e6099e8, topicName=米格列奈)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 24 05:26:00 CST 2013, time=2013-08-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636687, encodeId=0820163668ede, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Apr 02 22:26:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759299, encodeId=d66e1e592994f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Sep 09 06:26:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901104, encodeId=965e190110417, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Oct 26 01:26:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687670, encodeId=b581168e67091, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Fri Dec 06 14:26:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803921, encodeId=9f251803921b7, content=<a href='/topic/show?id=41bde6100af' target=_blank style='color:#2F92EE;'>#米格列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76100, encryptionId=41bde6100af, topicName=米格列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Oct 24 02:26:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803920, encodeId=424718039200e, content=<a href='/topic/show?id=b578e6099e8' target=_blank style='color:#2F92EE;'>#米格列奈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76099, encryptionId=b578e6099e8, topicName=米格列奈)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 24 05:26:00 CST 2013, time=2013-08-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636687, encodeId=0820163668ede, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Apr 02 22:26:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759299, encodeId=d66e1e592994f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Sep 09 06:26:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901104, encodeId=965e190110417, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Oct 26 01:26:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687670, encodeId=b581168e67091, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Fri Dec 06 14:26:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803921, encodeId=9f251803921b7, content=<a href='/topic/show?id=41bde6100af' target=_blank style='color:#2F92EE;'>#米格列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76100, encryptionId=41bde6100af, topicName=米格列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Oct 24 02:26:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803920, encodeId=424718039200e, content=<a href='/topic/show?id=b578e6099e8' target=_blank style='color:#2F92EE;'>#米格列奈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76099, encryptionId=b578e6099e8, topicName=米格列奈)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 24 05:26:00 CST 2013, time=2013-08-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1636687, encodeId=0820163668ede, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Apr 02 22:26:00 CST 2014, time=2014-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759299, encodeId=d66e1e592994f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Sep 09 06:26:00 CST 2013, time=2013-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901104, encodeId=965e190110417, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Oct 26 01:26:00 CST 2013, time=2013-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687670, encodeId=b581168e67091, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Fri Dec 06 14:26:00 CST 2013, time=2013-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803921, encodeId=9f251803921b7, content=<a href='/topic/show?id=41bde6100af' target=_blank style='color:#2F92EE;'>#米格列醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76100, encryptionId=41bde6100af, topicName=米格列醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Thu Oct 24 02:26:00 CST 2013, time=2013-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803920, encodeId=424718039200e, content=<a href='/topic/show?id=b578e6099e8' target=_blank style='color:#2F92EE;'>#米格列奈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76099, encryptionId=b578e6099e8, topicName=米格列奈)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Aug 24 05:26:00 CST 2013, time=2013-08-24, status=1, ipAttribution=)]
    2013-08-24 howi

相关资讯

JCEM:审视胰岛素在2型糖尿病中的应用价值

  1月31日,英国研究者在《临床内分泌与代谢杂志》发表了一项回顾性队列研究。研究者关注了胰岛素在2型糖尿病治疗中的安全性,研究分析显示,胰岛素与2型糖尿病患者的糖尿病相关并发症、癌症和全因死亡危险升高相关。尽管文章作者指出,在解读结果时应考虑到不同治疗组患者基线特征存在差异,此项研究仍引发医师和患者对于胰岛素治疗糖尿病的担忧和思考。因而,有必要深入分析此项研究,并回顾和审视胰岛素在2型糖尿病治疗

Diabetes Care:糖尿病患者强化血压控制增加冠心病风险

在糖尿病患者中,控制血压可以降低冠心病(CHD)的风险;然而,最低冠心病风险的糖尿病患者是否伴随最低的血压水平仍不清除。为此,来自美国路易斯安那州彭宁顿生物医学研究中心的Gang Hu教授及其团队进行了一项研究,该研究发现血压与CHD风险之间呈U字形相关或负相关,但是,在伴有糖尿病的非裔美籍和白种人患者中间,强化血压控制(血压<120/70mmHg)与CHD风险增加有关。该研究结果在线发表在201

Diabetes Res Clin Pr:TID儿童应该减少果糖的摄入

以往的研究显示,在成人,膳食果糖的高消耗引起血脂异常和血压升高,但在青少年,这方面的数据很少,特别是对那些处于心血管疾病(CVD)高风险的青少年。在1型糖尿病(T1D)青少年的多样化人群中,为了验证果糖摄入与CVD危险因素的关系。来自美国辛辛那提大学医学中心的Sarah C Couch教授及其团队进行了一项研究,该研究发现TID儿童,特别是那些伴有临界甘油三脂或高甘油三脂的儿童,应该减少果糖的摄入

Diabetes Care:工作压力增加妇女T2DM发病风险

为了研究工作压力对2 型糖尿病(T2D)的预期影响,来自瑞士斯德哥尔摩卡罗琳斯卡医学院医学系和临床流行病学组的Anna-Karin Eriksson博士等人进行了一项研究,研究发现,工作压力和轮班工作促进妇女T2D的发生。而在男性中,工作要求高、工作紧张度高以及积极的工作能够降低T2D风险。研究结果在线发表于2013年5月1日的美国《糖尿病治疗》(Diabetes Care)杂志上。 这是一项基

Diabetes Res Clin Pr:T2DM患者存在骨矿代谢失衡

在2型糖尿病(T2DM)患者中,为了评估糖尿病和糖尿病肾病对骨矿代谢的影响。来自中国兰州大学第二医院的陈慧教授及其团队进行了一项研究(The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients),该研究发现T2DM患者表现为骨矿代谢失衡,而且,合并

Diabetes Res Clin Pr:CAPD糖尿病患者的技术生存与非糖尿病患者相似

为了评估在中国南方地区,糖尿病患者持续非卧床腹膜透析(CAPD)的临床结局和影响生存的危险因素。来自中山大学第一附属医院肾内科的余学清教授及其团队进行了一项研究(Clinicaloutcome and risk factors for mortality in Chinese patients with diabetes on peritoneal dialysis: A 5-year clini

Baidu
map
Baidu
map
Baidu
map